FDA Grants Rare Disease Evidence Principles Eligibility to Repair Biotechnologies' mRNA Therapy for Homozygous Familial Hypercholesterolemia
核心洞察
Repair Biotechnologies (搜索) received FDA eligibility for the Rare Disease Evidence Principles program for REP-0003, an investigational mRNA therapy targeting homozygous familial hypercholesterolemia (搜索).
The RDEP designation allows substantial evidence of effectiveness to be demonstrated with one adequate clinical study, offering a streamlined approval pathway for this rare disease therapy.
REP-0003 utilizes a proprietary Cholesterol Degrading Platform that encodes an enzyme to degrade toxic excess free cholesterol (搜索), showing rapid plaque regression in preclinical studies.
Repair Biotechnologies (搜索) announced that the U.S. Food and Drug Administration has granted eligibility for the Rare Disease Evidence Principles (RDEP) program for its investigational messenger RNA therapy, REP-0003, in the treatment of homozygous familial hypercholesterolemia (搜索) (HoFH (搜索)). The designation represents a significant regulatory milestone that could accelerate the development timeline for this first-in-class therapy targeting a life-threatening genetic disorder.
Streamlined Regulatory Pathway
The RDEP eligibility aligns with the FDA's emphasis on mechanism of action-driven approvals and efficient development pathways for therapies addressing high unmet need rare diseases. Under RDEP, substantial evidence of effectiveness can be demonstrated with one adequate and well-controlled clinical study, supported by confirmatory evidence, offering a streamlined, science-based route to approval.
REP-0003 previously received Orphan Drug Designation from the FDA in May 2025 for the treatment of severe atherosclerosis (搜索) in patients with HoFH (搜索). The RDEP eligibility further strengthens Repair Biotechnologies (搜索)' collaborative relationship with the FDA as it advances this disease-modifying therapy.
Novel Mechanism of Action
REP-0003 is an mRNA therapy based on Repair Biotechnologies (搜索)' proprietary Cholesterol Degrading Platform (CDP). The therapy encodes an enzyme that selectively and safely degrades the previously undruggable target of toxic excess free cholesterol (搜索) inside cells into a non-toxic, readily excreted metabolite.
In preclinical studies using LDLR (搜索)-knockout mouse models of HoFH (搜索), addressing free cholesterol (搜索) toxicity with REP-0003 produced rapid regression of established atherosclerotic plaque, marked improvements in liver function, and enhanced exercise capacity.
Addressing Critical Unmet Need
HoFH (搜索) is a very rare, life-threatening genetic disorder caused primarily by mutations in both copies of the LDLR (搜索) gene. Patients exhibit extremely elevated LDL cholesterol from birth, leading to accelerated atherosclerosis (搜索), myocardial infarction (搜索), and premature cardiovascular death, often in childhood or early adulthood. Current treatments do not reliably or adequately control the condition, and carry significant tolerability, adherence, or access burdens.
"Receiving RDEP eligibility is a transformative validation of our science and the therapeutic potential of REP-0003 for patients with HoFH (搜索)," said Dr. Mourad Topors, the Chief Scientific Officer of Repair Biotechnologies (搜索). "Our Cholesterol Degrading Platform directly targets the intracellular free cholesterol (搜索) toxicity that drives accelerated plaque formation when LDLR (搜索) function is impaired. Our compelling preclinical data shows rapid plaque regression and functional recovery. This, combined with RDEP's flexible evidence framework, positions us to deliver a truly disease-modifying therapy that could dramatically improve outcomes and quality of life for patients."
Development Strategy
Reason, CEO of Repair Biotechnologies (搜索), emphasized the strategic importance of the FDA decision: "The FDA decision is very exciting. It derisks and accelerates our development program, emphasizing the strength and capability of our CDP platform. With Orphan Drug Designation in hand and now RDEP eligibility, we have a clear, efficient path forward that aligns with the Agency's evolving focus on mechanism-based innovation."
The company plans to open an Investigational New Drug (IND) application to enable continued close collaboration with the FDA at key development milestones. This regulatory strategy positions REP-0003 for potential accelerated development in a patient population with significant unmet medical need.
Repair Biotechnologies (搜索) develops first-in-class therapies that break down the undruggable target of toxic free cholesterol (搜索) inside cells to rapidly reduce arterial plaque in atherosclerosis (搜索) and familial hypercholesterolemia, reverse liver fibrosis (搜索) in metabolic disorders, and which have the potential to treat numerous other conditions associated with aging and obesity.